Axitinib

Active ingredient description

Axitinib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2 and VEGFR-3. These receptors are implicated in pathologic angiogenesis, tumour growth, and metastatic progression of cancer. Axitinib has been shown to potently inhibit VEGF-mediated endothelial cell proliferation and survival.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
L01EK01
Axitinib
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
Discover more medicines within L01EK01

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
INLYTA Film-coated tablet
Summary of Product Characteristics (SPC)

Medicines

Axitinib is the active ingredient of these drugs:

Drug
Countries
INCOX

Ecuador

INLYTA

Australia Austria Brazil Cyprus Ecuador

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₂₂H₁₈N₄OS
Molecular mass: 386.47 g/mol

External identifiers

CAS Substance: 319460-85-0
DrugBank Drug: DB06626
KEGG Drug: D03218
PubChem Compound: 6450551
RxNorm Ingredient: 1242999
SNOMED-CT Concept: 427882000
Axitinib (substance)
UNII Identifier: C9LVQ0YUXG
AXITINIB
 
Next: Usage >